2011 Midyear Clinical Meeting
Click here to go to the previous page
Oncology Pharmacy Specialty Sessions 2011: Advanced Topics in Practice, Part 1
Track:
Education Sessions (CE)
Date: Tuesday, December 6, 2011
Time: 8:00 AM to 11:00 AM EST
Location:
Room 272, Level 2
PRESENTER(S):
Michael Berger
Rebecca Greene
Julianna Merten
Ashley Morris Engemann, Clinical Associate, Duke University Medical Center Division of Cellular Therapy
PROGRAM CHAIR:
Julianna Merten
Description
Moderator: Julianna Merten, PharmD, BCPS, BCOP, Clinical Pharmacy Specialist, Mayo Clinic, Rochester, MN
Please note: If you are attending this program for BCOP recertification, there are different instructions for claiming CE from those attending only for ACPE credit.
ACPE Credit Only: Instructions for claiming CE will be available in the session room. CE will be provided by the Hematology/Oncology Pharmacy Association (HOPA).
BCOP Recertification: These sessions are part of the professional development program for recertification of Board Certified Oncology Pharmacists (BCOPs), approved by the Board of Pharmaceutical Specialties (BPS). Part 2 will be presented on Tuesday, December 6, 2:00 p.m. – 5:00 p.m. BCOPs must attend all six hours of programming to be eligible to complete the Web-based post-test for oncology recertification credit. Partial credit is not available for recertification, but is available for ACPE credit.
At the session room, you must complete a paper registration form and have the barcode on your name badge scanned both in the morning and afternoon sessions as you enter and exit the session room.
The post-test fee is $45. After the Midyear Clinical Meeting, program participants will receive email instructions to purchase and access the test, as well as claim ACPE credit. The post-test examination must be completed and submitted by December 31, 2011.
8:00 a.m. – 9:00 a.m.
Chronic Lymphocytic Leukemia
UAN# 0465-9999-11-303-L01-P
1.0 Contact Hour/Application-based
Presenter: Ashley Morris Engemann, PharmD, BCOP, Clinical Associate, Duke University Medical Center, Durham, NC
Learning Objectives:
Compare and contrast initial treatment strategies for patients presenting with symptomatic and /or advanced stage chronic lymphocytic leukemia (CLL).
Differentiate treatment options for management of relapsed or refractory CLL.
Justify the role of allogeneic stem cell transplantation in selected patient with CLL.
9:00 a.m. – 10:00 a.m.
Updates in the Treatment of Metastatic Breast Cancer
UAN# 0465-9999-11-301-L01-P
1.0 Contact Hour/Application-based
Presenter: Michael J. Berger, PharmD, BCOP, Specialty Practice Pharmacists, The Ohio State University Medical Center, Columbus
Learning Objectives:
Discern the role of bevacizumab in the management of patients with metastatic breast cancer (MBC).
Compare and contrast targeted therapies for the treatment of HER2(+) MBC.
Distinguish chemotherapy options for patients with anthracycline and taxane-refractory MBC.
10:00 a.m. – 11:00 a.m.
Castration-Resistant Prostate Cancer
UAN# 0465-9999-11-401-L01-P
1.0 Contact Hour/Application-based
Presenter: Rebecca Greene, PharmD, BCOP, Clinical Pharmacy Specialist, Oncology, South Texas Veterans health Care System, San Antonio
Learning Objectives:
Develop a treatment algorithm for castration-resistant prostate cancer (CRPC) based on the efficacy of the therapies.
Analyze patient –specific information to determine when a change in management is indicated in patients with CRPC.
Construct a treatment plan for a patient with CRPC based on prior therapy comorbid illness, and concomitant medications.
No items are available for this session.